Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in … Read more

Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch

Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch

Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that … Read more

Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

Drugmakers Roche and Sanofi’s latest earnings were largely as expected, with the companies talking up the potential of experimental medicines ahead of a looming “patent cliff” for Big Pharma. Both companies’ stocks were down less than 1% on Thursday after reporting earnings before the bell. They are both among the pharmaceutical companies that could see … Read more

UnitedHealth posts modest earnings beat, soft revenue guidance as insurer plots turnaround

UnitedHealth posts modest earnings beat, soft revenue guidance as insurer plots turnaround

UnitedHealth Group Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, Dec. 31, 2025. Michael Nagle | Bloomberg | Getty Images UnitedHealth Group on Tuesday posted a modest fourth-quarter earnings beat, but issued soft revenue guidance, as the parent company of the nation’s largest private insurer … Read more

Hyundai shares fall after Trump says tariffs on South Korean autos, pharma to rise to 25%

Hyundai shares fall after Trump says tariffs on South Korean autos, pharma to rise to 25%

U.S. President Donald Trump speaks at the 2025 Asia-Pacific Economic Cooperation (APEC) CEO Summit in Gyeongju, South Korea, October 29, 2025. Tyrone Siu | Reuters President Donald Trump said Monday that he was increasing tariffs on imported autos, pharmaceuticals, and lumber from South Korea from 15% to 25% because of a delay in that country’s … Read more

From French drug pricing to ‘loser’ windmills: A rundown of who Trump criticized at Davos

From French drug pricing to ‘loser’ windmills: A rundown of who Trump criticized at Davos

US President Donald Trump gestures as he delivers a special address during the World Economic Forum (WEF) annual meeting in Davos on January 21, 2026. The World Economic Forum takes place in Davos from January 19 to January 23, 2026. Mandel Ngan | Afp | Getty Images U.S. President Donald Trump backed away from tariffs … Read more

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase … Read more

Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch

Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill for obesity. In … Read more

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. … Read more

Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market

Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market

Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker … Read more